Laurus Labs Ltd
NSEI:LAURUSLABS
India / Healthcare / Pharmaceuticals
Exchange Data
Hide this widget
Price
561.25 INR
Day change
-13.20 (-2.30%)
52-week range
385.45 - 646.20
10:59 - Closed
Summary of Laurus Labs Ltd
Hide this widget
Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and intern...
Price History
Chart Gallery
Hide this widget
1 Week
1 Month
3 Months
1 Year
5 Year
10 Years
- (-)
Data Explorer
Hide this widget
Data could not be retrieved
Peer Benchmarks
Hide this widget
Quote
Value
Size
Growth
Profit
| LAURUSLABS | Peers | Sector | |
|---|---|---|---|
Market Cap | 302.7 B | 52.871 B | 5.212 B |
Price % of 52 Week High | Premium | 65.6% | 59.6% |
Dividend Yield | 0.1% | 0.4% | 0.0% |
Shareholder Yield | Premium | 0.0% | -0.7% |
1 Year Price Total Return | 28.0% | -3.2% | -14.8% |
Beta (5 Year) | 1.08 | 0.48 | 0.64 |
In the News
Hide this widget
Fair Value
Hide this widget
Average
–
Upside
–
Uncertainty
–
Spread
–
Financial Health
Health Details
Hide this widget
Financial Health for Laurus Labs is determined by ranking the company on over 100 factors against companies in the Healthcare sector and operating in Developing economic markets.
12345
Financial Models for Laurus Labs Ltd
Model Gallery
Hide this widget
| 10Y DCF EBITDA ExitView Updated 17 hours ago |
| 10Y DCF Revenue ExitView Updated 17 hours ago |
| 10Y DCF Growth ExitView Updated 17 hours ago |
| 5Y DCF EBITDA ExitView Updated 17 hours ago |
| 5Y DCF Revenue ExitView Updated 17 hours ago |
| 5Y DCF Growth ExitView Updated 17 hours ago |
| DDM Multi StageView Updated 17 hours ago |
| DuPont ROE AnalysisView Updated 5 hours ago |
| EV / EBIT MultiplesView Updated 17 hours ago |
| EV / EBITDA MultiplesView Updated 17 hours ago |
| P/E MultiplesView Updated 17 hours ago |
| Price / Book MultiplesView Updated 17 hours ago |
| Price / Sales MultiplesView Updated 17 hours ago |
| EV / Revenue MultiplesView Updated 17 hours ago |
| CAPM WACC ModelView Updated 1 day ago |
| DDM Stable GrowthView Updated 17 hours ago |
| Earnings Power ValueView Updated 17 hours ago |
| 10Y Historical FinancialsView Updated 5 hours ago |
| 5Y Historical FinancialsView Updated 5 hours ago |
Historical Financials
Full Financials
Hide this widget
| (INR in millions) | Trailing Twelve Months | Fiscal Quarters | |||
|---|---|---|---|---|---|
| Period Ending | Mar-23 | Mar-24 | Dec-24 | Dec-23 | Dec-24 |
| Income Statement | |||||
| Revenue | 60,406 | 50,408 | 52,733 | 11,949 | 14,151 |
| Operating Income | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Net Profit | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Diluted EPS | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| EBITDA | 16,059 | 7,629 | 8,668 | 1,633 | 2,711 |
| Balance Sheet | |||||
| Cash & ST Invest. | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Current Assets | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Total Assets | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Current Liabilities | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Total Liabilities | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Total Equity | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Total Debt | 20,151 | 25,774 | 27,890 | 21,343 | 27,890 |
| Cash Flow Statement | |||||
| Cash Flow Operations | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Cash From Investing | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Cash From Financing | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Free Cash Flow | 37 | (126) | (3,277) | 0.00 | - |
Analyst Notes
April 7, 2025
Hide this widget